<DOC>
	<DOCNO>NCT00391131</DOCNO>
	<brief_summary>This study aim assess safety , tolerability , efficacy pharmacokinetics Ig NextGen 16 % people antibody deficiency currently treat IntragamP . Ig NextGen 16 % liquid immunoglobulin ( antibody ) preparation manufacture use predominately chromatographic technique . Eligible patient switch monthly intravenous IntragamP therapy weekly subcutaneous Ig NextGen 16 % treatment . Initial hospital training require subcutaneous administration patient perform infusion home , return month supervise infusion . Patients monitor study 10 month assess blood IgG level rate serious bacterial infection .</brief_summary>
	<brief_title>Subcutaneous Ig NextGen 16 % PID Patients</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Males females 3 year age great least 13 kg enrolment . PID patient receive Ig replacement therapy , diagnosis Xlinked agammaglobulinemia ( XLA ) Common Variable immunodeficiency ( CVID ) severe hypogammaglobulinemia . Patients receive consistent dose Intragam®P 3 , 4 , 5 6weekly interval , within range 0.2 0.6 g/kg body weight , least six month prior Screening visit . Patients must maintain IgG trough serum level ≥ 5 g/L six month prior Visit 0 , least two trough level document period . Patients and/or legally acceptable representative/guardian must give write informed consent participate study must understand nature study must willing comply protocol requirement • Patients newly diagnose PID within six month Screening visit . Patients know suspect severe hypersensitivity previous evidence severe side effect immunoglobulin therapy blood product Patients known selective IgA deficiency antibody IgA Patients receive immunosuppressive treatment topical and/or inhale steroid low dose oral steroid . Females pregnant , breast feeding planning pregnancy course study . Females child bear potential must negative pregnancy test screening . Patients proteinlosing enteropathy , kidney disease substantial proteinuria Patients malignancies lymphoid cell chronic lymphocytic leukaemia , NonHodgkin 's lymphoma immunodeficiency thymoma . Patients within 30 day prior study screen visit , participate clinical study use investigational compound ( eg : new chemical entity register clinical use ) . Patients follow abnormal lab result : Serum creatinine &gt; 1.5 x Upper limit Normal ( ULN ) . Serum ALT &amp; AST &gt; 2.5 x ULN . Albumin &lt; 25 g/L Patients suffer acute chronic medical condition , PID , may , opinion Investigator , affect conduct trial . Patients willing unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>PID</keyword>
	<keyword>SCIG</keyword>
	<keyword>Ig</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Serious Bacterial Infections</keyword>
</DOC>